Definitive Contract HHSN272201400057C
Award Date
9/5/14
Potential Completion Date
3/7/16
Potential Value
$225K
Federal Agency
NIAID DEA OA Acquisitions
Awardee
Metallopharm LLC
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Delaware, OH 43015, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $744,075.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Coordinated Program Development LLC, a for-profit limited liability company. The contract is for the development of "OTHER FUNCTIONS - EFFICACY OF ORAL AMINOGLYCOSIDE-COCHLEATE FORMULATIONS", a research project focused on evaluating the effectiveness of certain drug...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government. The contract, with a ceiling value of $299,943.00, has been awarded to Lifetime Omics, Inc., a minority-owned, woman-owned, and small disadvantaged business. The contract is for research related to SBIR Topic 123, with a completion date of November 30, 2024. The contract is a definitive contract with a firm...
This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.
This is a $1,500,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Cure Systems LLC, a self-certified small disadvantaged business located in Newton, Massachusetts. The contract is for the research and development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies," a specialized approach to developing advanced...
This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Cellmic, LLC, a small business, in the amount of $224,661.00. The contract is for a TELE-MONITORING FOR INFECTIOUS DISEASES: A REMOTE SYSTEM FOR ASSESSING PATIENT PARAMETERS AND SPECIMEN ANALYSIS project under the SBIR Program Phase I. The contract is a Definitive Contract with a Firm Fixed Price pricing type and has an ultimate completion date of August 29, 2017. The...
<p>This federal contract award with ID HHSN272201200386P was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the small business contractor IG Assets Inc. The $99,750.00 firm fixed-price purchase order contract was awarded on April 10, 2012 with a completion date of April 28, 2013. The contract is designated as a total small business set-aside.</p>
This is a fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Pulmokine, Inc. for the development of "Aerosolized Delivery of Anti-Tubercular Drugs." The contract has a ceiling value of $224,960.00 and a period of performance ending on January 15, 2016. As an SBIR Phase I contract, this award supports early-stage research and...
This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Northbound Therapeutics, Inc., a minority-owned, woman-owned small business, to develop an inhaled clofazimine powder as a novel treatment for multidrug-resistant tuberculosis (MDR-TB). The contract, valued at $37,500, is for the formulation and preclinical evaluation of the inhaled clofazimine powder. This SBIR contract is a Firm Fixed Price...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...